Ocular Therapeutix (NASDAQ: OCUL) officer to sell 1,897 shares
Rhea-AI Filing Summary
OCULAR THERAPEUTIX, INC. (symbol OCUL) received a notice under Rule 144 that officer Sanjay Nayak intends to sell up to 1,897 shares of common stock. The shares relate to restricted stock vesting under a registered plan, with sales to be effected through Morgan Stanley Smith Barney LLC Executive Financial Services. The filing also reports that during the prior three months, Sanjay Nayak sold 1,858 shares of OCUL common stock on 05/26/2026 for $15,236.53.
Positive
- None.
Negative
- None.
Key Figures
Shares intended to be sold: 1,897 shares
Past 3 months shares sold: 1,858 shares
Proceeds from past sale: $15,236.53
+3 more
6 metrics
Shares intended to be sold
1,897 shares
Common stock to be sold by Sanjay Nayak under Rule 144
Past 3 months shares sold
1,858 shares
Common stock sold on 05/26/2026
Proceeds from past sale
$15,236.53
Total proceeds from 1,858 shares sold on 05/26/2026
Proposed transaction value
$20,452.70
Value associated with 1,897 shares in the securities information section
Approximate date of sale
08/22/2026
Date of sale for securities to be sold section
Form 144 signature date
08/24/2026
Date signed by /s/ Sanjay Nayak
Key Terms
Rule 144, Restricted Stock, registered plan, securities to be sold
4 terms
Rule 144 regulatory
"See the definition of "person" in paragraph (a) of Rule 144."
Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.
Restricted Stock financial
"Restricted Stock Vesting Under a Registered Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
registered plan financial
"Restricted Stock Vesting Under a Registered Plan"
A registered plan is a savings or investment account that a government recognizes for special tax treatment and rules, such as limits on how much you can put in and conditions for withdrawals. For investors it matters because those rules change how much of your gains are taxed, how quickly your money can be accessed and what strategies make sense — like a labeled jar that gives tax breaks but comes with rules about when and how you can take the money out.
securities to be sold financial
"144: Securities To Be Sold"
FAQ
What does the Form 144 filing disclose for OCUL?
The filing states that officer Sanjay Nayak intends to sell up to 1,897 shares of OCULAR THERAPEUTIX, INC. common stock under Rule 144, following restricted stock vesting under a registered plan, using Morgan Stanley Smith Barney LLC Executive Financial Services as broker.
What prior OCUL stock sales by Sanjay Nayak are reported in this Form 144?
The filing reports that 1,858 shares of OCULAR THERAPEUTIX, INC. common stock were sold by Sanjay Nayak on 05/26/2026 for total proceeds of $15,236.53 during the past three months.
Which broker is handling the planned OCUL stock sale under this Form 144?
The planned sale of OCULAR THERAPEUTIX, INC. common stock is to be handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
What is the relationship of the selling person to OCULAR THERAPEUTIX, INC. in this Form 144?
The selling person, Sanjay Nayak, is identified as an Officer of OCULAR THERAPEUTIX, INC. in connection with the planned Rule 144 sale of common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.